Curcumin extract improves beta cell functions in obese patients with type 2 diabetes: a randomized controlled trial
Background Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated blood glucose levels. Curcumin, a polyphenolic compound from Curcuma longa, has shown potential in improving insulin sensitivity and reducing blo...
Saved in:
| Published in | Nutrition journal Vol. 23; no. 1; p. 119 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
01.10.2024
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1475-2891 1475-2891 |
| DOI | 10.1186/s12937-024-01022-3 |
Cover
| Abstract | Background
Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated blood glucose levels. Curcumin, a polyphenolic compound from Curcuma longa, has shown potential in improving insulin sensitivity and reducing blood glucose levels, which may help mitigate type 2 diabetes progression.
Objective
To assess the efficacy of improving type 2 diabetes (T2DM).
Study design
This randomized, double-blind, placebo-controlled trial included subjects (
n
= 272) with criteria for type 2 diabetes.
Methods
All subjects were randomly assigned to receive curcumin (1500 mg/day) or placebo with blind labels for 12 months. To assess the improvement of T2DM after curcumin treatments body weight and body mass index, fasting plasma glucose, glycosylated hemoglobin A
1c,
β-cell function (homeostasis model assessment [HOMA-β]), insulin resistance (HOMA-IR), insulin, adiponectin, and leptin were monitored at the baseline and at 3-, 6-, 9-, and 12-month visits during the course of intervention.
Results
After 12 months of treatment, the curcumin-treated group showed a significant decrease in fasting blood glucose (115.49 vs.130.71;
P
< 0.05), HbA
1c
(6.12 vs. 6.47;
P
< 0.05). In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (136.20 vs. 105.19;
P
< 0.01) The curcumin-treated group showed a lower level of HOMA-IR (4.86 vs. 6.04;
P
< 0.001) and higher adiponectin (14.51 vs. 10.36;
P
< 0.001) when compared to the placebo group. The curcumin-treated group also showed a lower level of leptin (9.42 vs. 20.66;
P
< 0.001). Additionally, body mass index was lowered (25.9 4 vs.29.34), with a
P
value of 0.001.
Conclusions
A 12-month curcumin intervention in type 2 diabetes patients shows a significant glucose-lowering effect. Curcumin treatment appeared to improve the overall function of β-cells and reduce both insulin resistance and body weight, with very minor adverse effects. Curcumin intervention in obese patients with type 2 diabetes may be beneficial.
Trial registration
Thai clinical trials regentrify no.20140303003. |
|---|---|
| AbstractList | Background Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated blood glucose levels. Curcumin, a polyphenolic compound from Curcuma longa, has shown potential in improving insulin sensitivity and reducing blood glucose levels, which may help mitigate type 2 diabetes progression. Objective To assess the efficacy of improving type 2 diabetes (T2DM). Study design This randomized, double-blind, placebo-controlled trial included subjects (n = 272) with criteria for type 2 diabetes. Methods All subjects were randomly assigned to receive curcumin (1500 mg/day) or placebo with blind labels for 12 months. To assess the improvement of T2DM after curcumin treatments body weight and body mass index, fasting plasma glucose, glycosylated hemoglobin A.sub.1c, [beta]-cell function (homeostasis model assessment [HOMA-[beta]]), insulin resistance (HOMA-IR), insulin, adiponectin, and leptin were monitored at the baseline and at 3-, 6-, 9-, and 12-month visits during the course of intervention. Results After 12 months of treatment, the curcumin-treated group showed a significant decrease in fasting blood glucose (115.49 vs.130.71; P < 0.05), HbA.sub.1c (6.12 vs. 6.47; P < 0.05). In addition, the curcumin-treated group showed a better overall function of [beta]-cells, with higher HOMA-[beta] (136.20 vs. 105.19; P < 0.01) The curcumin-treated group showed a lower level of HOMA-IR (4.86 vs. 6.04; P < 0.001) and higher adiponectin (14.51 vs. 10.36; P < 0.001) when compared to the placebo group. The curcumin-treated group also showed a lower level of leptin (9.42 vs. 20.66; P < 0.001). Additionally, body mass index was lowered (25.9 4 vs.29.34), with a P value of 0.001. Conclusions A 12-month curcumin intervention in type 2 diabetes patients shows a significant glucose-lowering effect. Curcumin treatment appeared to improve the overall function of [beta]-cells and reduce both insulin resistance and body weight, with very minor adverse effects. Curcumin intervention in obese patients with type 2 diabetes may be beneficial. Trial registration Thai clinical trials regentrify no.20140303003. Keywords: Type 2 diabetes, Curcumin, Beta cell functions, Glycemic control, Weight management, Nutritional supplements Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated blood glucose levels. Curcumin, a polyphenolic compound from Curcuma longa, has shown potential in improving insulin sensitivity and reducing blood glucose levels, which may help mitigate type 2 diabetes progression. To assess the efficacy of improving type 2 diabetes (T2DM). This randomized, double-blind, placebo-controlled trial included subjects (n = 272) with criteria for type 2 diabetes. All subjects were randomly assigned to receive curcumin (1500 mg/day) or placebo with blind labels for 12 months. To assess the improvement of T2DM after curcumin treatments body weight and body mass index, fasting plasma glucose, glycosylated hemoglobin A β-cell function (homeostasis model assessment [HOMA-β]), insulin resistance (HOMA-IR), insulin, adiponectin, and leptin were monitored at the baseline and at 3-, 6-, 9-, and 12-month visits during the course of intervention. After 12 months of treatment, the curcumin-treated group showed a significant decrease in fasting blood glucose (115.49 vs.130.71; P < 0.05), HbA (6.12 vs. 6.47; P < 0.05). In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (136.20 vs. 105.19; P < 0.01) The curcumin-treated group showed a lower level of HOMA-IR (4.86 vs. 6.04; P < 0.001) and higher adiponectin (14.51 vs. 10.36; P < 0.001) when compared to the placebo group. The curcumin-treated group also showed a lower level of leptin (9.42 vs. 20.66; P < 0.001). Additionally, body mass index was lowered (25.9 4 vs.29.34), with a P value of 0.001. A 12-month curcumin intervention in type 2 diabetes patients shows a significant glucose-lowering effect. Curcumin treatment appeared to improve the overall function of β-cells and reduce both insulin resistance and body weight, with very minor adverse effects. Curcumin intervention in obese patients with type 2 diabetes may be beneficial. Thai clinical trials regentrify no.20140303003. Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated blood glucose levels. Curcumin, a polyphenolic compound from Curcuma longa, has shown potential in improving insulin sensitivity and reducing blood glucose levels, which may help mitigate type 2 diabetes progression. To assess the efficacy of improving type 2 diabetes (T2DM). This randomized, double-blind, placebo-controlled trial included subjects (n = 272) with criteria for type 2 diabetes. All subjects were randomly assigned to receive curcumin (1500 mg/day) or placebo with blind labels for 12 months. To assess the improvement of T2DM after curcumin treatments body weight and body mass index, fasting plasma glucose, glycosylated hemoglobin A.sub.1c, [beta]-cell function (homeostasis model assessment [HOMA-[beta]]), insulin resistance (HOMA-IR), insulin, adiponectin, and leptin were monitored at the baseline and at 3-, 6-, 9-, and 12-month visits during the course of intervention. After 12 months of treatment, the curcumin-treated group showed a significant decrease in fasting blood glucose (115.49 vs.130.71; P < 0.05), HbA.sub.1c (6.12 vs. 6.47; P < 0.05). In addition, the curcumin-treated group showed a better overall function of [beta]-cells, with higher HOMA-[beta] (136.20 vs. 105.19; P < 0.01) The curcumin-treated group showed a lower level of HOMA-IR (4.86 vs. 6.04; P < 0.001) and higher adiponectin (14.51 vs. 10.36; P < 0.001) when compared to the placebo group. The curcumin-treated group also showed a lower level of leptin (9.42 vs. 20.66; P < 0.001). Additionally, body mass index was lowered (25.9 4 vs.29.34), with a P value of 0.001. A 12-month curcumin intervention in type 2 diabetes patients shows a significant glucose-lowering effect. Curcumin treatment appeared to improve the overall function of [beta]-cells and reduce both insulin resistance and body weight, with very minor adverse effects. Curcumin intervention in obese patients with type 2 diabetes may be beneficial. Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated blood glucose levels. Curcumin, a polyphenolic compound from Curcuma longa, has shown potential in improving insulin sensitivity and reducing blood glucose levels, which may help mitigate type 2 diabetes progression.BACKGROUNDType 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated blood glucose levels. Curcumin, a polyphenolic compound from Curcuma longa, has shown potential in improving insulin sensitivity and reducing blood glucose levels, which may help mitigate type 2 diabetes progression.To assess the efficacy of improving type 2 diabetes (T2DM).OBJECTIVETo assess the efficacy of improving type 2 diabetes (T2DM).This randomized, double-blind, placebo-controlled trial included subjects (n = 272) with criteria for type 2 diabetes.STUDY DESIGNThis randomized, double-blind, placebo-controlled trial included subjects (n = 272) with criteria for type 2 diabetes.All subjects were randomly assigned to receive curcumin (1500 mg/day) or placebo with blind labels for 12 months. To assess the improvement of T2DM after curcumin treatments body weight and body mass index, fasting plasma glucose, glycosylated hemoglobin A1c, β-cell function (homeostasis model assessment [HOMA-β]), insulin resistance (HOMA-IR), insulin, adiponectin, and leptin were monitored at the baseline and at 3-, 6-, 9-, and 12-month visits during the course of intervention.METHODSAll subjects were randomly assigned to receive curcumin (1500 mg/day) or placebo with blind labels for 12 months. To assess the improvement of T2DM after curcumin treatments body weight and body mass index, fasting plasma glucose, glycosylated hemoglobin A1c, β-cell function (homeostasis model assessment [HOMA-β]), insulin resistance (HOMA-IR), insulin, adiponectin, and leptin were monitored at the baseline and at 3-, 6-, 9-, and 12-month visits during the course of intervention.After 12 months of treatment, the curcumin-treated group showed a significant decrease in fasting blood glucose (115.49 vs.130.71; P < 0.05), HbA1c (6.12 vs. 6.47; P < 0.05). In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (136.20 vs. 105.19; P < 0.01) The curcumin-treated group showed a lower level of HOMA-IR (4.86 vs. 6.04; P < 0.001) and higher adiponectin (14.51 vs. 10.36; P < 0.001) when compared to the placebo group. The curcumin-treated group also showed a lower level of leptin (9.42 vs. 20.66; P < 0.001). Additionally, body mass index was lowered (25.9 4 vs.29.34), with a P value of 0.001.RESULTSAfter 12 months of treatment, the curcumin-treated group showed a significant decrease in fasting blood glucose (115.49 vs.130.71; P < 0.05), HbA1c (6.12 vs. 6.47; P < 0.05). In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (136.20 vs. 105.19; P < 0.01) The curcumin-treated group showed a lower level of HOMA-IR (4.86 vs. 6.04; P < 0.001) and higher adiponectin (14.51 vs. 10.36; P < 0.001) when compared to the placebo group. The curcumin-treated group also showed a lower level of leptin (9.42 vs. 20.66; P < 0.001). Additionally, body mass index was lowered (25.9 4 vs.29.34), with a P value of 0.001.A 12-month curcumin intervention in type 2 diabetes patients shows a significant glucose-lowering effect. Curcumin treatment appeared to improve the overall function of β-cells and reduce both insulin resistance and body weight, with very minor adverse effects. Curcumin intervention in obese patients with type 2 diabetes may be beneficial.CONCLUSIONSA 12-month curcumin intervention in type 2 diabetes patients shows a significant glucose-lowering effect. Curcumin treatment appeared to improve the overall function of β-cells and reduce both insulin resistance and body weight, with very minor adverse effects. Curcumin intervention in obese patients with type 2 diabetes may be beneficial.Thai clinical trials regentrify no.20140303003.TRIAL REGISTRATIONThai clinical trials regentrify no.20140303003. Background Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated blood glucose levels. Curcumin, a polyphenolic compound from Curcuma longa, has shown potential in improving insulin sensitivity and reducing blood glucose levels, which may help mitigate type 2 diabetes progression. Objective To assess the efficacy of improving type 2 diabetes (T2DM). Study design This randomized, double-blind, placebo-controlled trial included subjects ( n = 272) with criteria for type 2 diabetes. Methods All subjects were randomly assigned to receive curcumin (1500 mg/day) or placebo with blind labels for 12 months. To assess the improvement of T2DM after curcumin treatments body weight and body mass index, fasting plasma glucose, glycosylated hemoglobin A 1c, β-cell function (homeostasis model assessment [HOMA-β]), insulin resistance (HOMA-IR), insulin, adiponectin, and leptin were monitored at the baseline and at 3-, 6-, 9-, and 12-month visits during the course of intervention. Results After 12 months of treatment, the curcumin-treated group showed a significant decrease in fasting blood glucose (115.49 vs.130.71; P < 0.05), HbA 1c (6.12 vs. 6.47; P < 0.05). In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (136.20 vs. 105.19; P < 0.01) The curcumin-treated group showed a lower level of HOMA-IR (4.86 vs. 6.04; P < 0.001) and higher adiponectin (14.51 vs. 10.36; P < 0.001) when compared to the placebo group. The curcumin-treated group also showed a lower level of leptin (9.42 vs. 20.66; P < 0.001). Additionally, body mass index was lowered (25.9 4 vs.29.34), with a P value of 0.001. Conclusions A 12-month curcumin intervention in type 2 diabetes patients shows a significant glucose-lowering effect. Curcumin treatment appeared to improve the overall function of β-cells and reduce both insulin resistance and body weight, with very minor adverse effects. Curcumin intervention in obese patients with type 2 diabetes may be beneficial. Trial registration Thai clinical trials regentrify no.20140303003. BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated blood glucose levels. Curcumin, a polyphenolic compound from Curcuma longa, has shown potential in improving insulin sensitivity and reducing blood glucose levels, which may help mitigate type 2 diabetes progression. OBJECTIVE: To assess the efficacy of improving type 2 diabetes (T2DM). STUDY DESIGN: This randomized, double-blind, placebo-controlled trial included subjects (n = 272) with criteria for type 2 diabetes. METHODS: All subjects were randomly assigned to receive curcumin (1500 mg/day) or placebo with blind labels for 12 months. To assess the improvement of T2DM after curcumin treatments body weight and body mass index, fasting plasma glucose, glycosylated hemoglobin A₁c, β-cell function (homeostasis model assessment [HOMA-β]), insulin resistance (HOMA-IR), insulin, adiponectin, and leptin were monitored at the baseline and at 3-, 6-, 9-, and 12-month visits during the course of intervention. RESULTS: After 12 months of treatment, the curcumin-treated group showed a significant decrease in fasting blood glucose (115.49 vs.130.71; P < 0.05), HbA₁c (6.12 vs. 6.47; P < 0.05). In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (136.20 vs. 105.19; P < 0.01) The curcumin-treated group showed a lower level of HOMA-IR (4.86 vs. 6.04; P < 0.001) and higher adiponectin (14.51 vs. 10.36; P < 0.001) when compared to the placebo group. The curcumin-treated group also showed a lower level of leptin (9.42 vs. 20.66; P < 0.001). Additionally, body mass index was lowered (25.9 4 vs.29.34), with a P value of 0.001. CONCLUSIONS: A 12-month curcumin intervention in type 2 diabetes patients shows a significant glucose-lowering effect. Curcumin treatment appeared to improve the overall function of β-cells and reduce both insulin resistance and body weight, with very minor adverse effects. Curcumin intervention in obese patients with type 2 diabetes may be beneficial. TRIAL REGISTRATION: Thai clinical trials regentrify no.20140303003. Abstract Background Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated blood glucose levels. Curcumin, a polyphenolic compound from Curcuma longa, has shown potential in improving insulin sensitivity and reducing blood glucose levels, which may help mitigate type 2 diabetes progression. Objective To assess the efficacy of improving type 2 diabetes (T2DM). Study design This randomized, double-blind, placebo-controlled trial included subjects (n = 272) with criteria for type 2 diabetes. Methods All subjects were randomly assigned to receive curcumin (1500 mg/day) or placebo with blind labels for 12 months. To assess the improvement of T2DM after curcumin treatments body weight and body mass index, fasting plasma glucose, glycosylated hemoglobin A1c, β-cell function (homeostasis model assessment [HOMA-β]), insulin resistance (HOMA-IR), insulin, adiponectin, and leptin were monitored at the baseline and at 3-, 6-, 9-, and 12-month visits during the course of intervention. Results After 12 months of treatment, the curcumin-treated group showed a significant decrease in fasting blood glucose (115.49 vs.130.71; P < 0.05), HbA1c (6.12 vs. 6.47; P < 0.05). In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (136.20 vs. 105.19; P < 0.01) The curcumin-treated group showed a lower level of HOMA-IR (4.86 vs. 6.04; P < 0.001) and higher adiponectin (14.51 vs. 10.36; P < 0.001) when compared to the placebo group. The curcumin-treated group also showed a lower level of leptin (9.42 vs. 20.66; P < 0.001). Additionally, body mass index was lowered (25.9 4 vs.29.34), with a P value of 0.001. Conclusions A 12-month curcumin intervention in type 2 diabetes patients shows a significant glucose-lowering effect. Curcumin treatment appeared to improve the overall function of β-cells and reduce both insulin resistance and body weight, with very minor adverse effects. Curcumin intervention in obese patients with type 2 diabetes may be beneficial. Trial registration Thai clinical trials regentrify no.20140303003. |
| ArticleNumber | 119 |
| Audience | Academic |
| Author | Jansarikit, Laddawan Yaikwawong, Metha Chuengsamarn, Somlak Jirawatnotai, Siwanon |
| Author_xml | – sequence: 1 givenname: Metha surname: Yaikwawong fullname: Yaikwawong, Metha organization: Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University – sequence: 2 givenname: Laddawan surname: Jansarikit fullname: Jansarikit, Laddawan organization: Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University – sequence: 3 givenname: Siwanon surname: Jirawatnotai fullname: Jirawatnotai, Siwanon organization: Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Siriraj Center of Research Excellence for Precision Medicine and Systems, Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Faculty of Pharmacy, Silpakorn University – sequence: 4 givenname: Somlak surname: Chuengsamarn fullname: Chuengsamarn, Somlak email: somlukc@hotmail.com organization: Division of Endocrinology and Metabolism, Faculty of Medicine, HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39354480$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkktr3DAUhU1JaZJp_0AXRdBNu3Cqpy13E8LQx0Cg0MdayPL1RIMtTSU56fTXV5OZhkwpIWghIX3ncHXPPS2OnHdQFC8JPiNEVu8ioQ2rS0x5iQmmtGRPihPCa1FS2ZCje-fj4jTGFcZUyqZ-VhyzhgnOJT4p4nwKZhqtQ_ArBW0SsuM6-GuIqIWkkYFhQP3kTLLeRZQ530IEtNbJgksR3dh0hdJmDYiizuosgvgeaRS06_xof0OHjHcp-GHIxxSsHp4XT3s9RHix32fFj48fvs8_l5dfPi3mF5elqXidStlKU5maEkEq1msgTLYEJGW0kkZQ2ROBcSWI0T02bUU7qmnX19AK3nW9qdisWOx8O69Xah3sqMNGeW3V7YUPS6VDsmYABUwy6A3nNadZXUsuRS8I7xpZt4Sa7MV2XpNb682NHoY7Q4LVNg61i0PlONRtHIpl1flOtZ7aETqTOxb0cFDK4YuzV2rpr7Mh56LJRc2KN3uH4H9OEJMabdyGoh34KSpGBJNE4qZ5BEooIaKqaEZf79Clzp-3rvfb7Le4upAES4F5JTJ19h8qrw5Gm0OF3ub7A8HbA8E2-DxWSz3FqBbfvh6yr-635q4nf0czA3IHmOBjDNArY5PejmGuwg4Pt53-I31UVvuEY4bdEoJa-Sm4PKAPqf4A-FMWQA |
| CitedBy_id | crossref_primary_10_1016_j_rechem_2025_102139 crossref_primary_10_3390_ph18020279 crossref_primary_10_3390_biom14121497 |
| Cites_doi | 10.2337/dc12-0116 10.1111/bph.13621 10.1210/er.2017-00111 10.2337/diacare.14.2.95 10.1007/s10787-016-0301-4 10.2174/1389450118666170328122527 10.2337/cd16-0067 10.1002/ptr.5341 10.1186/s13098-019-0437-7 10.1007/s00125-002-1009-0 10.1016/j.redox.2013.09.003 10.1016/S0197-2456(98)00037-3 10.1002/mnfr.201200131 10.3389/fphar.2016.00288 10.3390/diseases4030028 10.2337/db22-952-P 10.1016/j.jdiacomp.2013.12.002 10.1016/j.ctim.2019.02.014 10.1139/cjpp-2016-0152 10.1016/j.jnutbio.2013.09.013 10.4103/2468-8827.184853 10.1016/j.clnu.2004.04.010 10.1007/BF00280883 10.5754/hge11219 10.1016/S0140-6736(16)31678-6 10.1007/s00125-022-05787-2 10.5604/01.3001.0010.0307 10.1038/s41430-018-0382-9 10.1002/ptr.6328 10.1177/0003319714568792 10.3389/fendo.2021.585887 10.1016/j.biotechadv.2014.04.004 10.1021/jf0483873 10.2337/diacare.27.6.1487 10.1016/j.diabres.2009.10.007 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. The Author(s) 2024 2024 |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: The Author(s) 2024 2024 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 7X8 7S9 L.6 5PM ADTOC UNPAY DOA |
| DOI | 10.1186/s12937-024-01022-3 |
| DatabaseName | SpringerLink Journals Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic AGRICOLA |
| Database_xml | – sequence: 1 dbid: C6C name: SpringerOpen Free (Free internet resource, activated by CARLI) url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: Openly Available Collection - DOAJ url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology Diet & Clinical Nutrition |
| EISSN | 1475-2891 |
| EndPage | 119 |
| ExternalDocumentID | oai_doaj_org_article_e383efc447424dd78485f514d987b12c 10.1186/s12937-024-01022-3 PMC11445938 A810850465 39354480 10_1186_s12937_024_01022_3 |
| Genre | Randomized Controlled Trial Journal Article |
| GeographicLocations | Thailand |
| GeographicLocations_xml | – name: Thailand |
| GrantInformation_xml | – fundername: Thailand Research Fund grantid: 022/2012 funderid: http://dx.doi.org/10.13039/501100004396 – fundername: Ministry of Public Health grantid: 29/2013 funderid: http://dx.doi.org/10.13039/501100004397 – fundername: Ministry of Public Health grantid: 29/2013 – fundername: Thailand Research Fund grantid: 022/2012 |
| GroupedDBID | --- 04C 0R~ 123 29N 2WC 2XV 53G 5VS 7RQ 7RV 7X7 88E 8C1 8FI 8FJ 8G5 A8Z AAFWJ AAHBH AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS AZQEC BAPOH BAWUL BCNDV BENPR BFQNJ BKEYQ BMC BMSDO BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 DWQXO E3Z EAD EAP EAS EBD EBLON EBS ECGQY EIHBH EMB EMK EMOBN ESTFP ESX EX3 F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HH5 HMCUK HYE IAO ICU IHR IHT INH INR IPT ISE ISR ITC KQ8 M1P M2O M48 M~E NAPCQ O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO QF4 QN7 RBZ RNS ROL RPM RSV SCM SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX CITATION ALIPV CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 5PM 2VQ 4.4 ADTOC AHSBF C1A EJD H13 IPNFZ RIG UNPAY |
| ID | FETCH-LOGICAL-c647t-8b8c6c7215163fae138b1e823268c528f1500651caf0cb62d2a2df7eb54ddfc63 |
| IEDL.DBID | M48 |
| ISSN | 1475-2891 |
| IngestDate | Fri Oct 03 12:50:02 EDT 2025 Sun Oct 26 04:02:15 EDT 2025 Tue Sep 30 17:07:14 EDT 2025 Thu Oct 02 10:40:27 EDT 2025 Thu Sep 04 19:01:48 EDT 2025 Mon Oct 20 22:49:01 EDT 2025 Mon Oct 20 16:55:50 EDT 2025 Thu Oct 16 15:50:50 EDT 2025 Thu Apr 03 07:06:31 EDT 2025 Thu Apr 24 23:10:41 EDT 2025 Wed Oct 01 03:48:49 EDT 2025 Sat Sep 06 07:30:15 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Type 2 diabetes Glycemic control Curcumin Beta cell functions Weight management Nutritional supplements |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c647t-8b8c6c7215163fae138b1e823268c528f1500651caf0cb62d2a2df7eb54ddfc63 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12937-024-01022-3 |
| PMID | 39354480 |
| PQID | 3112115662 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_e383efc447424dd78485f514d987b12c unpaywall_primary_10_1186_s12937_024_01022_3 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11445938 proquest_miscellaneous_3153818099 proquest_miscellaneous_3112115662 gale_infotracmisc_A810850465 gale_infotracacademiconefile_A810850465 gale_incontextgauss_ISR_A810850465 pubmed_primary_39354480 crossref_citationtrail_10_1186_s12937_024_01022_3 crossref_primary_10_1186_s12937_024_01022_3 springer_journals_10_1186_s12937_024_01022_3 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-10-01 |
| PublicationDateYYYYMMDD | 2024-10-01 |
| PublicationDate_xml | – month: 10 year: 2024 text: 2024-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Nutrition journal |
| PublicationTitleAbbrev | Nutr J |
| PublicationTitleAlternate | Nutr J |
| PublicationYear | 2024 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | G Roglic (1022_CR1) 2016; 1 1022_CR35 1022_CR4 H Hodaei (1022_CR28) 2019; 11 TM Wallace (1022_CR34) 2004; 27 PP Toth (1022_CR7) 2015; 6 WD Dupont (1022_CR25) 1998; 19 S-B Syarifah-Noratiqah (1022_CR15) 2018; 19 M Gil-Campos (1022_CR38) 2004; 23 MW Schwartz (1022_CR30) 2017; 38 MJ Davies (1022_CR5) 2022; 65 T Nishiyama (1022_CR26) 2005; 53 DR Matthews (1022_CR23) 1985; 28 JE Shaw (1022_CR2) 2010; 87 S Chuengsamarn (1022_CR19) 2012; 35 ME Kelany (1022_CR17) 2017; 95 S Prasad (1022_CR11) 2014; 32 S Saadati (1022_CR27) 2019; 73 T Vos (1022_CR3) 2016; 388 SE Kahn (1022_CR33) 2003; 46 HR Rahimi (1022_CR31) 2016; 6 S Asadi (1022_CR37) 2019; 43 M Huang (1022_CR9) 2016; 7 AD Association (1022_CR20) 2017; 35 J Trujillo (1022_CR12) 2013; 1 S-G Zhao (1022_CR18) 2011; 58 LX Na (1022_CR36) 2013; 57 M Obradovic (1022_CR39) 2021; 12 M Adibian (1022_CR29) 2019; 33 AB Kunnumakkara (1022_CR40) 2017; 174 JC Brand (1022_CR22) 1991; 14 S Chuengsamarn (1022_CR24) 2014; 28 K Griffiths (1022_CR14) 2016; 4 OP Gulati (1022_CR8) 2015; 29 AM Patti (1022_CR6) 2015; 66 Y Panahi (1022_CR10) 2017; 25 S Chuengsamarn (1022_CR13) 2014; 25 AM Elmansi (1022_CR16) 2017; 16 American Diabetes Association (1022_CR21) 2013; 36 DR Matthews (1022_CR32) 1985; 28 |
| References_xml | – volume: 35 start-page: 2121 issue: 11 year: 2012 ident: 1022_CR19 publication-title: Diabetes Care doi: 10.2337/dc12-0116 – volume: 174 start-page: 1325 issue: 11 year: 2017 ident: 1022_CR40 publication-title: Br J Pharmacol doi: 10.1111/bph.13621 – volume: 38 start-page: 267 issue: 4 year: 2017 ident: 1022_CR30 publication-title: Endocr Rev doi: 10.1210/er.2017-00111 – volume: 14 start-page: 95 issue: 2 year: 1991 ident: 1022_CR22 publication-title: Diabetes Care doi: 10.2337/diacare.14.2.95 – ident: 1022_CR4 – volume: 25 start-page: 25 issue: 1 year: 2017 ident: 1022_CR10 publication-title: Inflammopharmacology doi: 10.1007/s10787-016-0301-4 – volume: 19 start-page: 927 issue: 8 year: 2018 ident: 1022_CR15 publication-title: Curr Drug Targets doi: 10.2174/1389450118666170328122527 – volume: 35 start-page: 5 issue: 1 year: 2017 ident: 1022_CR20 publication-title: Clin Diabetes: Publication Am Diabetes Association doi: 10.2337/cd16-0067 – volume: 29 start-page: 949 issue: 7 year: 2015 ident: 1022_CR8 publication-title: Phytother Res doi: 10.1002/ptr.5341 – volume: 11 start-page: 41 year: 2019 ident: 1022_CR28 publication-title: Diabetol Metab Syndr doi: 10.1186/s13098-019-0437-7 – volume: 46 start-page: 3 issue: 1 year: 2003 ident: 1022_CR33 publication-title: Diabetologia doi: 10.1007/s00125-002-1009-0 – volume: 1 start-page: 448 issue: 1 year: 2013 ident: 1022_CR12 publication-title: Redox Biol doi: 10.1016/j.redox.2013.09.003 – volume: 19 start-page: 589 issue: 6 year: 1998 ident: 1022_CR25 publication-title: Control Clin Trials doi: 10.1016/S0197-2456(98)00037-3 – volume: 57 start-page: 1569 issue: 9 year: 2013 ident: 1022_CR36 publication-title: Mol Nutr Food Res doi: 10.1002/mnfr.201200131 – volume: 7 start-page: 288 year: 2016 ident: 1022_CR9 publication-title: Front Pharmacol doi: 10.3389/fphar.2016.00288 – volume: 4 start-page: 28 issue: 3 year: 2016 ident: 1022_CR14 publication-title: Diseases doi: 10.3390/diseases4030028 – ident: 1022_CR35 doi: 10.2337/db22-952-P – volume: 28 start-page: 124 issue: 2 year: 2014 ident: 1022_CR24 publication-title: J Diabetes Complicat doi: 10.1016/j.jdiacomp.2013.12.002 – volume: 43 start-page: 253 year: 2019 ident: 1022_CR37 publication-title: Complement Ther Med doi: 10.1016/j.ctim.2019.02.014 – volume: 95 start-page: 140 issue: 2 year: 2017 ident: 1022_CR17 publication-title: Can J Physiol Pharmacol doi: 10.1139/cjpp-2016-0152 – volume: 25 start-page: 144 issue: 2 year: 2014 ident: 1022_CR13 publication-title: J Nutr Biochem doi: 10.1016/j.jnutbio.2013.09.013 – volume: 1 start-page: 3 issue: 1 year: 2016 ident: 1022_CR1 publication-title: Int J Noncommunicable Dis doi: 10.4103/2468-8827.184853 – volume: 23 start-page: 963 issue: 5 year: 2004 ident: 1022_CR38 publication-title: Clin Nutr doi: 10.1016/j.clnu.2004.04.010 – volume: 28 start-page: 412 issue: 7 year: 1985 ident: 1022_CR23 publication-title: Diabetologia doi: 10.1007/BF00280883 – volume: 6 start-page: 299 year: 2015 ident: 1022_CR7 publication-title: Front Pharmacol – volume: 58 start-page: 2106 issue: 112 year: 2011 ident: 1022_CR18 publication-title: Hepatogastroenterology doi: 10.5754/hge11219 – volume: 36 start-page: S4 issue: Suppl 1 year: 2013 ident: 1022_CR21 publication-title: Diabetes Care – volume: 28 start-page: 412 year: 1985 ident: 1022_CR32 publication-title: Diabetologia doi: 10.1007/BF00280883 – volume: 388 start-page: 1545 issue: 10053 year: 2016 ident: 1022_CR3 publication-title: Lancet doi: 10.1016/S0140-6736(16)31678-6 – volume: 65 start-page: 1925 issue: 12 year: 2022 ident: 1022_CR5 publication-title: Diabetologia doi: 10.1007/s00125-022-05787-2 – volume: 16 start-page: 607 issue: 4 year: 2017 ident: 1022_CR16 publication-title: Ann Hepatol doi: 10.5604/01.3001.0010.0307 – volume: 73 start-page: 441 issue: 3 year: 2019 ident: 1022_CR27 publication-title: Eur J Clin Nutr doi: 10.1038/s41430-018-0382-9 – volume: 33 start-page: 1374 issue: 5 year: 2019 ident: 1022_CR29 publication-title: Phytother Res doi: 10.1002/ptr.6328 – volume: 66 start-page: 856 issue: 9 year: 2015 ident: 1022_CR6 publication-title: Angiology doi: 10.1177/0003319714568792 – volume: 12 start-page: 585887 year: 2021 ident: 1022_CR39 publication-title: Front Endocrinol doi: 10.3389/fendo.2021.585887 – volume: 32 start-page: 1053 issue: 6 year: 2014 ident: 1022_CR11 publication-title: Biotechnol Adv doi: 10.1016/j.biotechadv.2014.04.004 – volume: 53 start-page: 959 issue: 4 year: 2005 ident: 1022_CR26 publication-title: J Agric Food Chem doi: 10.1021/jf0483873 – volume: 27 start-page: 1487 issue: 6 year: 2004 ident: 1022_CR34 publication-title: Diabetes Care doi: 10.2337/diacare.27.6.1487 – volume: 87 start-page: 4 issue: 1 year: 2010 ident: 1022_CR2 publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2009.10.007 – volume: 6 start-page: 567 issue: 5 year: 2016 ident: 1022_CR31 publication-title: Avicenna J Phytomedicine |
| SSID | ssj0028897 |
| Score | 2.4695456 |
| Snippet | Background
Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated... Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated blood glucose... Background Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated... BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated... Abstract Background Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to... |
| SourceID | doaj unpaywall pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 119 |
| SubjectTerms | adiponectin Adiponectin - blood Adult Beta cell functions blood glucose Blood Glucose - drug effects Blood Glucose - metabolism Body Mass Index body weight Body Weight - drug effects Care and treatment Clinical Nutrition Complications and side effects Curcuma Curcuma longa Curcumin Curcumin - administration & dosage Curcumin - pharmacology Development and progression Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Double-Blind Method Female Glycated Hemoglobin Glycemic control glycemic effect glycosylation Health aspects Health Promotion and Disease Prevention hemoglobin homeostasis Humans insulin Insulin - blood Insulin Resistance Insulin-Secreting Cells - drug effects Insulin-Secreting Cells - metabolism leptin Leptin - blood Male Medicine Medicine & Public Health Middle Aged noninsulin-dependent diabetes mellitus Nutritional supplements Obesity Obesity - complications Obesity - drug therapy Pancreatic beta cells Physiological aspects placebos Plant Extracts - administration & dosage Plant Extracts - pharmacology randomized clinical trials Turmeric Type 2 diabetes Weight management |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQL8ABQcsjUJBBCA406iZ2HC-3pVAVJHoAKvVmxa-yUjZbNRuh8uuZcZzVBqSFA7dVPHuIZzzzzWTmMyEvQc-uZLlLSyvxCjNpUq0ByCG61YIXrOQ4nPz5VJyc8U_nxfnGVV_YE9bTA_cbd-gghXLecA45HLe2lFwWHqK8hWRZZ7lB7zuR0yGZiqmWlNNyGJGR4rDFqFamEI_SwKGWslEYCmz9f_rkjaD0e8Pk-qvpbXKzay6r6x9VXW8EpuO75E5ElHTWv8k9csM1u2Rv1kA2vbimr2jo8QzF812SvJ-7FTyLbKA1PR3I-PdIe9RdmW4xbyj4a5ydovNQcHAt1W5VUSzxUwyDwVIpyC21ax2NzKwtxZIuxZIuzelQ0n1LKwrR0C4X85_O0tgYX8PPcF3IfXJ2_OHb0Ukar2RIjeDlKpVaGmFKxAmC-cplTOrMSYBlQpoilx7wJYCazFR-YrTIbV7l1pdOF6A7bwR7QHaaZeMeESo0HH7vOCs9R5uomLSm1MYK6y2gmoRkg4aUiXzleG1GrULeIoXqtapAqypoVbGEvFn_57Jn69gq_Q4Vv5ZEpu3wAOxPRftTf7O_hLxAs1HIpdFgs85F1bWt-vj1i5pJHO2YcFEk5HUU8kvUYBVnH2AnkH5rJLk_koTDbkbLzwfrVLiEHXKNW3atYhmS9QE4z7fJFAjQIClIyMPeotcvjyPakKpPEiJHtj7anfFKM_8e-MghpebFlMmEHAzHQkVP2G7d_oP10fkHbT3-H9p6Qm7l6AVCN-Y-2Vldde4poMqVfhYcyC-X8m9M priority: 102 providerName: Directory of Open Access Journals – databaseName: SpringerLink Journals Open Access dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdgSHw8IOj4CAxkEIIHFtHEju3yVgrTQNoegEl7s-KPQKU2nZZGaPz13LlO1ACa4K2KL5XiO_t-d777mZAXoGcvWe5T6RReYaZsagwAOUS3RvCCSY7NyUfH4vCEfzotTiNNDvbCbJ_fZ0q8adAfyRQ8SRrYz1J2lVwDJyXCwayY9cGVUhPZNcX89b2B4wn8_H_uwltu6PcSyf6c9Ba50dZn5cWPcrHYckUHd8jtiCHpdKP0u-SKr0dkd1pD_Ly8oC9pqOoM6fIRSd7P_RqeRf7PBT3u6PdH5PpRPFjfJc2sPbftcl5T2KyxcYrOQ7bBN9T4dUkxv0_RBwYzpSC3Mr7xNNKyNhTzuRTzuTSnXT73LS0puEK3Ws5_ekdjVfwCfoa7Qu6Rk4MPX2eHabyPIbWCy3WqjLLCSgQJglWlz5gymVeAyYSyRa4qAJeAaDJbVmNrRO7yMneV9KbgzlVWsPtkp17V_iGhwsDKrzxnsuJoECVTzkpjnXCVA0iTkKxTlraRrBzvzFjoELQooTcK1qBgHRSsWUJe9--cbag6LpV-hzbQSyLNdngA1qfjqtUe4ndfWc4lz-EbpOKqqABiuomSJsttQp6jBWkk0qixUudb2TaN_vjls54q7OsYc1Ek5FUUqlaowTI2PsBMIPfWQHJvIAkr3Q6Gn3WGqnEIy-Nqv2obzTJk6gNknl8mUyA6g4ggIQ82xt1_PPZnQ5w-TogamP1gdoYj9fx7ICOHeJoXE6YSst-tEB23webS6d_vV9E_aOvR__37Y3Izx6Ufii73yM76vPVPADyuzdOwa_wCaa9jRA priority: 102 providerName: Springer Nature – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZgewAOPFoegYIMQnCgKZvYsV1uS6EqSKwQUKmcrPgRWLGbrZpEqP31zHiT1aagVblFyeRgex7f2DOfCXkO6-wlS30sncIrzJSNjQEgh-jWCJ4xybE5-dNYHB7xj8fZcUuTg70wq-f3iRKvK4xHMoZIEgf2s5hdJRsiA9w9IBtH48-j76F9SGYxZA5J1xXzzx97kScQ9P_thlfi0MUayeVB6Q1yrSlP8rPf-XS6EosObi0uNaoChSGWoPzabWqza88vEDxebpi3yc0WktLRQofukCu-3CRboxLS8dkZfUFDkWjYfd8k0buJr-FdSyc6peOOzX-LVPvNqW1mk5KCw8fmKzoJOxa-osbXOcUzAopxNKg6Bbm58ZWnLbVrRXFPmOKeME1ptyf8huYUwqmbzybn3tG2sn4Kj-G-kbvk6OD9t_3DuL3TIbaCyzpWRllhJQINwYrcJ0yZxCvAdULZLFUFAFRARYnNi6E1InVpnrpCepNx5wor2D0yKOelf0CoMOA9Cs-ZLDgqVc6Us9JYJ1zhABZFJOnWW9uW8Bzv3ZjqkPgooRezrmHWdZh1zSLyavnPyYLuY630W1SjpSRSdYcXsLS6tXztmWK-sJxLnsIYpOIqKwCmuj0lTZLaiDxDJdRIxlFitc-PvKkq_eHrFz1S2Bsy5CKLyMtWqJjjCuZt8wTMBPJ39SS3e5LgLWzv89NO1zV-whK70s-bSrME2f4A3afrZDJEeJBVROT-wj6Wg8ceb8j1hxFRPcvpzU7_Szn5GQjNISfn2R5TEdnpjEy3rrRaO_07S0O8xGo9_D_xR-R6ivYYCje3yaA-bfxjAKC1edJ6nj97Wnhn priority: 102 providerName: Unpaywall |
| Title | Curcumin extract improves beta cell functions in obese patients with type 2 diabetes: a randomized controlled trial |
| URI | https://link.springer.com/article/10.1186/s12937-024-01022-3 https://www.ncbi.nlm.nih.gov/pubmed/39354480 https://www.proquest.com/docview/3112115662 https://www.proquest.com/docview/3153818099 https://pubmed.ncbi.nlm.nih.gov/PMC11445938 https://doi.org/10.1186/s12937-024-01022-3 https://doaj.org/article/e383efc447424dd78485f514d987b12c |
| UnpaywallVersion | publishedVersion |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVFSB databaseName: Free Full-Text Journals in Chemistry customDbUrl: eissn: 1475-2891 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0028897 issn: 1475-2891 databaseCode: HH5 dateStart: 20020101 isFulltext: true titleUrlDefault: http://abc-chemistry.org/ providerName: ABC ChemistRy – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1475-2891 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0028897 issn: 1475-2891 databaseCode: RBZ dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1475-2891 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0028897 issn: 1475-2891 databaseCode: KQ8 dateStart: 20020901 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1475-2891 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0028897 issn: 1475-2891 databaseCode: KQ8 dateStart: 20020101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: Openly Available Collection - DOAJ customDbUrl: eissn: 1475-2891 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0028897 issn: 1475-2891 databaseCode: DOA dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1475-2891 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0028897 issn: 1475-2891 databaseCode: ABDBF dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVEBS databaseName: EBSCOhost Food Science Source customDbUrl: eissn: 1475-2891 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0028897 issn: 1475-2891 databaseCode: A8Z dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/login.aspx?authtype=ip,uid&profile=ehost&defaultdb=fsr providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1475-2891 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0028897 issn: 1475-2891 databaseCode: DIK dateStart: 20020101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1475-2891 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0028897 issn: 1475-2891 databaseCode: GX1 dateStart: 20020101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1475-2891 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0028897 issn: 1475-2891 databaseCode: M~E dateStart: 20020101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central (Free e-resource, activated by CARLI) customDbUrl: eissn: 1475-2891 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0028897 issn: 1475-2891 databaseCode: RPM dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection (Proquest) customDbUrl: eissn: 1475-2891 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0028897 issn: 1475-2891 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1475-2891 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0028897 issn: 1475-2891 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Proquest Public Health Database customDbUrl: eissn: 1475-2891 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0028897 issn: 1475-2891 databaseCode: 8C1 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1475-2891 dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0028897 issn: 1475-2891 databaseCode: M48 dateStart: 20020901 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: HAS SpringerNature Open Access 2022 customDbUrl: eissn: 1475-2891 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0028897 issn: 1475-2891 databaseCode: AAJSJ dateStart: 20021201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerOpen Free (Free internet resource, activated by CARLI) customDbUrl: eissn: 1475-2891 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0028897 issn: 1475-2891 databaseCode: C6C dateStart: 20020112 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELf28QA8INj4CIzKIAQPLNAkju0iIdSVTaPSqmmjUnmyYscZldp0NK2g_PXcuUm0wDTtpa3sa6T47ny_s--DkNfAZyui0PoildjCTBpfawByiG41Z3EkGCYnnwz48ZD1R_Fog1TtjsoFLK517bCf1HA-ef_75-ozKPwnp_CSfyjQZgkfrI3vKqT50SbZBkvVwVYOJ6y-VQilXDdbYSL2wdEIqiSaa5_RMFSunv__u_YVs_VvSGV9r3qP3Fnml8nqVzKZXDFdRw_I_RJz0u5aSB6SDZvvkN1uDv72dEXfUBcF6o7Xd4j3ZWwXMFbWC53QQVWuf5cUveXcLKfjnMKOjtlVdOyOJGxBtV0kFC8BKBpKJ8sU6GbaFpaWtVsLioe-FA99aUirQ9-PNKFgL9PZdPzHprQMnZ_AT9dQ5BEZHh1-6x37ZdMG33AmFr7U0nAjEEnwKEtsEEkdWAnAjUsThzIDBAqwJzBJ1jaah2mYhGkmrI5ZmmaGR4_JVj7L7VNCuYbtIbMsEhlDqUkimRqhTcrTLAXc45Gg4pAyZUVzbKwxUc6zkVytuaqAq8pxVUUeeVf_53Jdz-NG6gNkfE2JtbjdwGx-oUrVVhacfJsZxgQL4R2EZDLOAIemHSl0EBqPvEKxUVhtI8dwnotkWRTq6_mZ6kpM_mgzHnvkbUmUzZCDSZkdASuBBboalHsNStgOTGP6ZSWdCqcwhi63s2WhogDL-QF8D2-iiRHCgdvgkSdria5fHpO4wZlve0Q2ZL2xOs2ZfPzDVSwHp5vFnUh6ZL9SC1Wp-o3Lv1-rzi249ew2C_2c3A1Ry1085h7ZWsyX9gXgyoVukU0xEvApe0GLbHe7_fM-fB8cDk7PYLTHey13YtNymwrMDAen3e9_AWIYdqk |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdgkxg8IOj4CAwwCMHDFtEkju3yVgZTV9Y-sE3amxU7zqjUplPTCo2_njvXiRZAFbxV8aVSfN_nu58JeQt8tiKJbShyiVeYSRNqDYEcRreaszQRDIeTR2M-OGfDi_TCD4VVdbd7fSTpLLVTa8k_VOiZRAg-JXQ4aGFym2xjkxWo43a_PzwdNomWlD1RD8j89c2WE3JY_X9a5Bsu6fd2yebM9B7ZWZVX2fWPbDq94ZaOHpD7Pp6k_bUAPCS3bNkhu_0ScunZNX1HXYenK513SPB5YpfwzGOBTum4huLvkDsjf8i-S6rD1cKsZpOSguHGISo6cZUHW1FtlxnFWj9Ff-hElgLdXNvKUg_RWlGs7VKs7dKY1rXdjzSj4Bbz-Wzy0-bUd8hP4ae7N-QROT_6cnY4CP3dDKHhTCxDqaXhRmDAwJMis1EidWQlxGdcmjSWBQSaEN1EJiu6RvM4j7M4L4TVKcvzwvDkMdkq56V9SijXYAUKyxJRMBSOLJG5EdrkPC9yCG8CEtXMUsYDl-P9GVPlEhjJ1ZrBChisHINVEpD95p2rNWzHRupPKAMNJUJuuwfzxaXyGqws5PK2MIwJFsM3CMlkWkC4mfek0FFsAvIGJUghqEaJXTuX2aqq1PHpN9WXOOPRZTwNyHtPVMyRg5kfgoCdQByuFuVeixK03rSWX9eCqnAJW-VKO19VKokQtQ-i9HgTTYqRGmQHAXmyFu7m43FWG3L2bkBkS-xbu9NeKSffHTA55NYs7SUyIAe1hihvEquN23_QaNE_cOvZ__37K7IzOBudqJPj8dfn5G6MZsA1Y-6RreViZV9AULnUL70N-QXspmud |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdgSAMeEHR8BAYYhOBhi9Ykju3yVjqqDViFgEl7s-KPjEptWjWN0PjruXOTqgFUwVsVXyrFd_b97nz3MyGvQM9OJLELhZV4hZk0odYA5BDdas7SRDBsTj4b8ZNz9uEivdjo4vfV7s2R5KqnAVmaiuXR3OarJS75UYleSoTgX0LPiRYm18kNBt4N7zAY8ME65JKyJ5pWmb--13JHnrX_z715wzn9Xji5Pj29TW5WxTy7-pFNJhsOaniX3KmRJe2vTOEeueaKDtnrFxBVT6_oa-prPX0SvUOC47FbwrOaFXRCRw0pf4fsntXH7XukHFQLU03HBYUtHNup6NjnIFxJtVtmFLP-FD2jN14KcjPtSkdrstaSYpaXYpaXxrTJ8r6lGQUHaWfT8U9naV0rP4Gf_gaR--R8-P7b4CSsb2kIDWdiGUotDTcCoQNP8sxFidSRk4DUuDRpLHOAnIBzIpPlXaN5bOMstrlwOmXW5oYnD8hOMSvcI0K5hv0gdywROUMzyRJpjdDGcptbADoBiRplKVNTmONNGhPlQxnJ1UrBChSsvIJVEpCD9TvzFYHHVul3aANrSSTf9g9mi0tVr2XlIKp3uWFMsBi-QUgm0xyAp-1JoaPYBOQlWpBCeo0C63cus6os1enXL6ovsdujy3gakDe1UD5DDWZ1OwTMBDJytST3W5Kw_k1r-EVjqAqHsGiucLOqVEmE_H2A1-NtMiliNogTAvJwZdzrj8eubYjeuwGRLbNvzU57pBh_9xTlEGWztJfIgBw2K0TVm2O5dfoP16voH7T1-P_-_TnZ_Xw8VJ9ORx-fkFsx7gK-KnOf7CwXlXsK6HKpn_kN5Bfmx256 |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZgewAOPFoegYIMQnCgKZvYsV1uS6EqSKwQUKmcrPgRWLGbrZpEqP31zHiT1aagVblFyeRgex7f2DOfCXkO6-wlS30sncIrzJSNjQEgh-jWCJ4xybE5-dNYHB7xj8fZcUuTg70wq-f3iRKvK4xHMoZIEgf2s5hdJRsiA9w9IBtH48-j76F9SGYxZA5J1xXzzx97kScQ9P_thlfi0MUayeVB6Q1yrSlP8rPf-XS6EosObi0uNaoChSGWoPzabWqza88vEDxebpi3yc0WktLRQofukCu-3CRboxLS8dkZfUFDkWjYfd8k0buJr-FdSyc6peOOzX-LVPvNqW1mk5KCw8fmKzoJOxa-osbXOcUzAopxNKg6Bbm58ZWnLbVrRXFPmOKeME1ptyf8huYUwqmbzybn3tG2sn4Kj-G-kbvk6OD9t_3DuL3TIbaCyzpWRllhJQINwYrcJ0yZxCvAdULZLFUFAFRARYnNi6E1InVpnrpCepNx5wor2D0yKOelf0CoMOA9Cs-ZLDgqVc6Us9JYJ1zhABZFJOnWW9uW8Bzv3ZjqkPgooRezrmHWdZh1zSLyavnPyYLuY630W1SjpSRSdYcXsLS6tXztmWK-sJxLnsIYpOIqKwCmuj0lTZLaiDxDJdRIxlFitc-PvKkq_eHrFz1S2Bsy5CKLyMtWqJjjCuZt8wTMBPJ39SS3e5LgLWzv89NO1zV-whK70s-bSrME2f4A3afrZDJEeJBVROT-wj6Wg8ceb8j1hxFRPcvpzU7_Szn5GQjNISfn2R5TEdnpjEy3rrRaO_07S0O8xGo9_D_xR-R6ivYYCje3yaA-bfxjAKC1edJ6nj97Wnhn |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Curcumin+extract+improves+beta+cell+functions+in+obese+patients+with+type+2+diabetes%3A+a+randomized+controlled+trial&rft.jtitle=Nutrition+journal&rft.au=Yaikwawong%2C+Metha&rft.au=Jansarikit%2C+Laddawan&rft.au=Jirawatnotai%2C+Siwanon&rft.au=Chuengsamarn%2C+Somlak&rft.date=2024-10-01&rft.pub=BioMed+Central+Ltd&rft.issn=1475-2891&rft.eissn=1475-2891&rft.volume=23&rft.issue=1&rft_id=info:doi/10.1186%2Fs12937-024-01022-3&rft.externalDBID=ISR&rft.externalDocID=A810850465 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2891&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2891&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2891&client=summon |